Patient characteristics
| Pretreatment characteristic (N = 237) . | Number (%), median (range) . |
|---|---|
| Males | 144 (61) |
| Age ≥65 years | 51 (21) |
| Age (years) | 59 (32-84) |
| Rai stage III-IV | 96 (40) |
| ALC (K/μL) | 75 (1-425) |
| ALC ≥75 K/μL | 119 (50) |
| Hb (g/dL) | 12 (6.9-16.5) |
| PLT (K/μL) | 142 (12-398) |
| B2M ≥4 mg/L (n = 231) | 95 (41) |
| B2M (mg/L) | 3.6 (1.3-14.1) |
| Unmutated IGHV gene (n = 208) | 126 (61) |
| CD38 ≥30% (n = 225) | 97 (43) |
| CD38 (%) | 16 (0.1-99.9) |
| ZAP70 IHC positive (n= 214) | 138 (64) |
| FISH (n = 222) | |
| del(13q) | 73 (33) |
| negative | 47 (21) |
| +12 | 39 (18) |
| del(11q) | 47 (21) |
| del(17p) | 16 (7) |
| Pretreatment characteristic (N = 237) . | Number (%), median (range) . |
|---|---|
| Males | 144 (61) |
| Age ≥65 years | 51 (21) |
| Age (years) | 59 (32-84) |
| Rai stage III-IV | 96 (40) |
| ALC (K/μL) | 75 (1-425) |
| ALC ≥75 K/μL | 119 (50) |
| Hb (g/dL) | 12 (6.9-16.5) |
| PLT (K/μL) | 142 (12-398) |
| B2M ≥4 mg/L (n = 231) | 95 (41) |
| B2M (mg/L) | 3.6 (1.3-14.1) |
| Unmutated IGHV gene (n = 208) | 126 (61) |
| CD38 ≥30% (n = 225) | 97 (43) |
| CD38 (%) | 16 (0.1-99.9) |
| ZAP70 IHC positive (n= 214) | 138 (64) |
| FISH (n = 222) | |
| del(13q) | 73 (33) |
| negative | 47 (21) |
| +12 | 39 (18) |
| del(11q) | 47 (21) |
| del(17p) | 16 (7) |
ALC, absolute lymphocyte count; Hb, hemoglobin; IHC, immunohistochemistry; PLT, platelet.